Selskabsmeddelelse
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Genmab A/S
MEDDELELSE
ID:
123599
Type:
Intern viden
Sprog:
Engelsk
Dokument(er):
TIDSPUNKTER
Offentliggjort:
31.07.2020 | 21:38:12
Registrering:
31.07.2020 | 21:38:16
INDBERETTER
Virksomhed:
GlobeNewswire
CVR-nr.:
UK-02775270